The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.
 
Heather H. Cheng
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I)
Research Funding - Clovis Oncology (Inst); Color Genomics Foundation (Inst); Janssen (Inst); Medivation/Astellas (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Janssen
 
Samuel Callis
No Relationships to Disclose
 
Daniel W. Lin
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lantheus Medical Imaging
Research Funding - GenomeDx (Inst); Magforce (Inst); MDxHealth (Inst)
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; Janssen Oncology; Sanofi/Aventis
Research Funding - Pfizer (Inst)
 
Adam McLain Kase
No Relationships to Disclose
 
Catherine Tangen
No Relationships to Disclose
 
Daniel P. Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Seth P. Lerner
Stock and Other Ownership Interests - Aura Biosciences; C2i genomics
Honoraria - Grand Rounds in Urology; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; Ferring; Pfizer/EMD Serono; Protara Therapeutics; Stimit; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate